Cargando…

RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	He, Miao, Sun, Hai-Gang, Hao, Jun-Ying, Li, Yan-Lin, Yu, Jian-Kun, Yan, Yuan-Yuan, Zhao, Lin, Li, Na, Wang, Yan, Bai, Xue-Feng, Yu, Zhao-Jin, Zheng, Zhi-Hong, Mi, Xiao-Yi, Wang, En-Hua, Wei, Min-Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115629/ https://www.ncbi.nlm.nih.gov/pubmed/35543152 http://dx.doi.org/10.3892/or.2022.8327

Ejemplares similares

RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation
por: HE, MIAO, et al.
Publicado: (2013)

Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response
por: Lin, Shu, et al.
Publicado: (2019)

Correction: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response
por: Lin, Shu, et al.
Publicado: (2022)

Gene Silencing of FANCF Potentiates the Sensitivity to Mitoxantrone through Activation of JNK and p38 Signal Pathways in Breast Cancer Cells
por: Li, Yanlin, et al.
Publicado: (2012)

Protective effect of astragalosides from Radix Astragali on adriamycin-induced podocyte injury
por: Sai, Yi-Pa, et al.
Publicado: (2018)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

Serum Metabolic Profiling in a Mouse Model of Adriamycin-Induced Focal Segmental Glomerulosclerosis
por: Lyu, Li, et al.
Publicado: (2018)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
por: He, Ye, et al.
Publicado: (2015)

TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells
por: Chen, Li, et al.
Publicado: (2019)

Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations
por: Coldwell, Kate E., et al.
Publicado: (2008)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

Protective effect of melatonin against Adriamycin-induced cardiotoxicity
por: ZHANG, YAN, et al.
Publicado: (2013)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

Impact of ethyl pyruvate on Adriamycin-induced cardiomyopathy in rats
por: Liu, Menglin, et al.
Publicado: (2016)

Hypoxia‐inducible factor‐2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin
por: He, Miao, et al.
Publicado: (2019)

Identification of adriamycin resistance genes in breast cancer based on microarray data analysis
por: Chen, Yan, et al.
Publicado: (2020)

Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
por: Luo, Li-Fei, et al.
Publicado: (2021)

Adriamycin cardiotoxicity monitoring by radionuclide scan.
por: Robinson, B. A., et al.
Publicado: (1983)

Artemether ameliorates adriamycin induced cardiac atrophy in mice
por: Weng, Wenci, et al.
Publicado: (2023)

Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats
por: Zhang, Wei, et al.
Publicado: (2008)

Apoptosis and remodeling in adriamycin-induced cardiomyopathy rat model
por: Hong, Young Mi, et al.
Publicado: (2017)

Effects of the Combination of Gliotoxin and Adriamycin on the Adriamycin-Resistant Non-Small-Cell Lung Cancer A549 Cell Line
por: Manh Hung, Le Van, et al.
Publicado: (2018)

Acute Induction of Adriamycin‐resistance in Human Colon Carcinoma HT‐29 Cells Exposed to a Sublethal Dose of Adriamycin
por: Tomida, Akihiro, et al.
Publicado: (1995)

No Evidence for FANCF Gene Silencing in Head-and-Neck Squamous Cell Carcinomas
por: Ameziane, Najim, et al.
Publicado: (2009)

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer
por: Lim, S L, et al.
Publicado: (2008)

Endothelin Receptor A Blockade Is an Ineffective Treatment for Adriamycin Nephropathy
por: Tan, Roderick J., et al.
Publicado: (2013)

Hyperoside alleviates adriamycin-induced podocyte injury via inhibiting mitochondrial fission
por: Chen, Zhuyun, et al.
Publicado: (2017)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

Cytotoxicity of adriamycin to tumour cells in vivo and in vitro.
por: Martin, W. M., et al.
Publicado: (1980)

Different distribution of adriamycin in normal and leukaemic rats.
por: Sonneveld, P., et al.
Publicado: (1981)

A Sarcoma at the Site of Previous Extravasation of Adriamycin
por: Ceulemans, Joris, et al.
Publicado: (2002)

An in vivo assessment of adriamycin-loaded albumin microspheres.
por: Goldberg, J. A., et al.
Publicado: (1992)

Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats
por: Mansouri, Esrafil, et al.
Publicado: (2018)

Preventive role of carvedilol in adriamycin-induced cardiomyopathy
por: Jhorawat, Rajesh, et al.
Publicado: (2016)

Adriamycin does not damage podocytes of zebrafish larvae
por: Schindler, Maximilian, et al.
Publicado: (2020)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

YB-1 Expression Is Associated with Lymph Node Metastasis and Drug Resistance to Adriamycin in Breast Cancer
por: Dong, Hanzhi, et al.
Publicado: (2023)

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
por: Cao, Bei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1i7kdbs2num3ivnla3j6lcvhp4